BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12.
Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing blood-borne pathogens in donated blood components intended for transfusion.
Dr. Lavin said adoption of this completely new method within blood facilities and with various governments has taken and will take time, “the bottom line is Cerus should be well positioned for accelerating growth by 2021.”
Noting that Cerus shares are at a “multi-year low for reasons we do not understand, it seems now would be a superb time to acquire shares.”